Status:
COMPLETED
Study of CP-675,206 in Refractory Melanoma
Lead Sponsor:
AstraZeneca
Conditions:
Refractory Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune...
Eligibility Criteria
Inclusion
- Surgically incurable Stage III or IV melanoma
- One prior systemic treatment for metastatic melanoma
- Measurable disease
- Eastern Cooperative Oncology Group (ECOG) PS = 0 or 1
Exclusion
- Melanoma of ocular origin
- Received prior vaccine
- Received prior CTLA4-inhibiting agent
- History of, or significant risk for, chronic inflammatory or autoimmune disease
- Potential requirement for systemic corticosteroids
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
251 Patients enrolled
Trial Details
Trial ID
NCT00254579
Start Date
December 1 2005
End Date
December 1 2009
Last Update
June 7 2012
Active Locations (65)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Scottsdale, Arizona, United States, 85260
2
Research Site
Bentonville, Arkansas, United States, 72712
3
Research Site
Fayetteville, Arkansas, United States, 72703
4
Research Site
Little Rock, Arkansas, United States, 72205